Theratechnologies to begin Phase II of ThGRF 1-44

Theratechnologies (TSE:TH) filed an IND in Canada to begin a Phase II double-blind, placebo-controlled trial to determine the safety and efficacy of ThGRF 1-44, a growth hormone releasing factor analo...